Network-Based Drug Discovery: Coupling Network Pharmacology with Phenotypic Screening for Neuronal Excitability

被引:36
|
作者
Sidders, Ben [1 ,2 ]
Karlsson, Anna [3 ]
Kitching, Linda [1 ,4 ]
Torella, Rubben [5 ]
Karila, Paul [3 ]
Phelan, Anne [1 ,6 ]
机构
[1] Pfizer Res & Dev, Neusentis, Cambridge CB21 6GS, England
[2] AstraZeneca, IMED Biotech Unit, Biosci, Oncol, Cambridge CB2 0RE, England
[3] Cellectricon, S-43137 Molndal, Sweden
[4] BenevolentAl Cambridge Ltd, Cambridge CB22 3AT, England
[5] Pfizer World Wide Res & Dev, Cambridge, MA 02139 USA
[6] Mission Therapeut, Cambridge CB22 3AT, England
关键词
network-based drug discovery; neuroscience; pain; drug repurposing; PAIN; EXPRESSION; CURRENTS;
D O I
10.1016/j.jmb.2018.07.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diseases such as chronic pain with complex etiologies are unlikely to respond to single, target-specific therapeutics but rather require intervention at multiple points within a perturbed disease system. Such approaches are being enabled by the rise of computational methods to identify key points of intervention and by new screening techniques that focus on a relevant condition or phenotype, rather than a specific target. Here we apply an in silico network pharmacology approach to identify small-molecule compounds with the potential to selectively disrupt the structure of a chronic-pain specific disease network, which we validate using a novel phenotypic screen that recapitulates key aspects of neuronal and pain biology by measuring changes in neuronal excitability in native sensory neurons. The combination of network pharmacology with a phenotypic screen is a powerful approach; we show that hit rates increase from 26% to 42%. This represents a rational approach to the discovery of compounds with a poly-pharmacology based therapeutic value, which will be vital for the discovery of treatments for complex disease. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3005 / 3015
页数:11
相关论文
共 50 条
  • [22] Network-based prediction of drug combinations
    Cheng, Feixiong
    Kovacs, Istvan A.
    Barabasi, Albert-Laszlo
    [J]. NATURE COMMUNICATIONS, 2019, 10 (1)
  • [23] Complex network-based approaches to biomarker discovery
    Hayashida, Morihiro
    Akutsu, Tatsuya
    [J]. BIOMARKERS IN MEDICINE, 2016, 10 (06) : 621 - 632
  • [24] Network-based drug repurposing for schizophrenia
    Trang T. T. Truong
    Zoe S. J. Liu
    Bruna Panizzutti
    Jee Hyun Kim
    Olivia M. Dean
    Michael Berk
    Ken Walder
    [J]. Neuropsychopharmacology, 2024, 49 : 983 - 992
  • [25] Network-Based Approaches for Drug Repositioning
    Song, Tao
    Wang, Gan
    Ding, Mao
    Rodriguez-Paton, Alfonso
    Wang, Xun
    Wang, Shudong
    [J]. MOLECULAR INFORMATICS, 2022, 41 (05)
  • [26] Network-based drug sensitivity prediction
    Ahmed, Khandakar Tanvir
    Park, Sunho
    Jiang, Qibing
    Yeu, Yunku
    Hwang, TaeHyun
    Zhang, Wei
    [J]. BMC MEDICAL GENOMICS, 2020, 13 (Suppl 11)
  • [27] Network-based prediction of drug combinations
    Feixiong Cheng
    István A. Kovács
    Albert-László Barabási
    [J]. Nature Communications, 10
  • [28] Network-based drug sensitivity prediction
    Khandakar Tanvir Ahmed
    Sunho Park
    Qibing Jiang
    Yunku Yeu
    TaeHyun Hwang
    Wei Zhang
    [J]. BMC Medical Genomics, 13
  • [29] Netrank: network-based approach for biomarker discovery
    Al-Fatlawi, Ali
    Rusadze, Eka
    Shmelkin, Alexander
    Malekian, Negin
    Ozen, Cigdem
    Pilarsky, Christian
    Schroeder, Michael
    [J]. BMC BIOINFORMATICS, 2023, 24 (01)
  • [30] Network-based drug repurposing for schizophrenia
    Truong, Trang T. T.
    Liu, Zoe S. J.
    Panizzutti, Bruna
    Kim, Jee Hyun
    Dean, Olivia M.
    Berk, Michael
    Walder, Ken
    [J]. NEUROPSYCHOPHARMACOLOGY, 2024, 49 (06) : 983 - 992